State Street Corp Invests $777,000 in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

State Street Corp bought a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 48,592 shares of the company's stock, valued at approximately $777,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nantahala Capital Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth $4,064,000. Ally Bridge Group NY LLC bought a new position in Centessa Pharmaceuticals in the third quarter worth about $4,951,000. Driehaus Capital Management LLC lifted its position in shares of Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock valued at $18,891,000 after buying an additional 987,997 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Centessa Pharmaceuticals by 66.1% in the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company's stock worth $1,498,000 after buying an additional 37,275 shares during the last quarter. Finally, First Light Asset Management LLC raised its stake in shares of Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock worth $43,168,000 after acquiring an additional 1,778,515 shares in the last quarter. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA traded down $0.49 during trading on Friday, hitting $17.01. The stock had a trading volume of 586,192 shares, compared to its average volume of 553,296. The stock has a 50-day simple moving average of $16.84 and a two-hundred day simple moving average of $14.06. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -11.12 and a beta of 1.52. Centessa Pharmaceuticals plc has a 12-month low of $6.65 and a 12-month high of $18.97. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CTO Tia L. Bush sold 17,813 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the transaction, the chief technology officer now directly owns 147,615 shares of the company's stock, valued at $2,657,070. The trade was a 10.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saurabh Saha sold 2,592 shares of the stock in a transaction on Wednesday, October 23rd. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44. Following the sale, the chief executive officer now directly owns 630,661 shares in the company, valued at $9,661,726.52. This trade represents a 0.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 368,023 shares of company stock valued at $6,335,574. 11.59% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Morgan Stanley raised shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Jefferies Financial Group boosted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, September 11th. Guggenheim increased their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, November 15th. BMO Capital Markets boosted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research note on Monday, September 16th. Finally, B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a "buy" rating and a $33.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $25.83.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.